PURPOSE: To determine the prognostic significance of a multimarker assay incorporating expression levels of three molecular markers in primary cutaneous melanoma. EXPERIMENTAL DESIGN: We assessed expression levels of NCOA3, SPP1, and RGS1 using immunohistochemical analysis in a tissue microarray cohort of 395 patients. For each marker, we identified optimal cut-points for expression intensity to predict disease-specific survival (DSS) and, as a secondary endpoint, sentinel lymph node (SLN) status. The cumulative overexpression of all three markers was embodied in a multimarker index, and its prognostic effect on DSS and SLN status was assessed using Cox regression, Kaplan-Meier analysis, and logistic regression. The prognostic effect of this multimarker assay on DSS was assessed in an independent cohort of 141 patients, in which marker expression levels were scored using immunohistochemical analysis of stained tissue sections. RESULTS: Increasing multimarker index scores were significantly predictive of reduced DSS and increased SLN metastasis in the 395-patient cohort. Multivariate logistic regression analysis revealed multimarker expression scores as an independent predictor of SLN status (P = 0.001). Multivariate Cox regression analysis showed the independent effect of the multimarker index on DSS (P < 0.001). The multimarker index was the most significant factor predicting DSS when compared with other clinical and histologic factors, including SLN status (P = 0.002). Multimarker expression scores were also the most significantly predictive of DSS in the independent cohort (P = 0.01). CONCLUSIONS: These results describe a multimarker assay with independent prognostic effect on the prediction of survival associated with melanoma in two distinct cohorts.
PURPOSE: To determine the prognostic significance of a multimarker assay incorporating expression levels of three molecular markers in primary cutaneous melanoma. EXPERIMENTAL DESIGN: We assessed expression levels of NCOA3, SPP1, and RGS1 using immunohistochemical analysis in a tissue microarray cohort of 395 patients. For each marker, we identified optimal cut-points for expression intensity to predict disease-specific survival (DSS) and, as a secondary endpoint, sentinel lymph node (SLN) status. The cumulative overexpression of all three markers was embodied in a multimarker index, and its prognostic effect on DSS and SLN status was assessed using Cox regression, Kaplan-Meier analysis, and logistic regression. The prognostic effect of this multimarker assay on DSS was assessed in an independent cohort of 141 patients, in which marker expression levels were scored using immunohistochemical analysis of stained tissue sections. RESULTS: Increasing multimarker index scores were significantly predictive of reduced DSS and increased SLN metastasis in the 395-patient cohort. Multivariate logistic regression analysis revealed multimarker expression scores as an independent predictor of SLN status (P = 0.001). Multivariate Cox regression analysis showed the independent effect of the multimarker index on DSS (P < 0.001). The multimarker index was the most significant factor predicting DSS when compared with other clinical and histologic factors, including SLN status (P = 0.002). Multimarker expression scores were also the most significantly predictive of DSS in the independent cohort (P = 0.01). CONCLUSIONS: These results describe a multimarker assay with independent prognostic effect on the prediction of survival associated with melanoma in two distinct cohorts.
Authors: Izidore S Lossos; Debra K Czerwinski; Ash A Alizadeh; Mark A Wechser; Rob Tibshirani; David Botstein; Ronald Levy Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: Christopher Haqq; Mehdi Nosrati; Daniel Sudilovsky; Julia Crothers; Daniel Khodabakhsh; Brian L Pulliam; Scot Federman; James R Miller; Robert E Allen; Mark I Singer; Stanley P L Leong; Britt-Marie Ljung; Richard W Sagebiel; Mohammed Kashani-Sabet Journal: Proc Natl Acad Sci U S A Date: 2005-04-15 Impact factor: 11.205
Authors: J E Gershenwald; W Thompson; P F Mansfield; J E Lee; M I Colome; C H Tseng; J J Lee; C M Balch; D S Reintgen; M I Ross Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: Mohammed Kashani-Sabet; Ladan Shaikh; James R Miller; Mehdi Nosrati; Carlos M M Ferreira; Robert J Debs; Richard W Sagebiel Journal: J Clin Oncol Date: 2004-02-15 Impact factor: 44.544
Authors: Keith Wheatley; Natalie Ives; Barry Hancock; Martin Gore; Alexander Eggermont; Stefan Suciu Journal: Cancer Treat Rev Date: 2003-08 Impact factor: 12.111
Authors: Vijay Kumar Eedunuri; Kimal Rajapakshe; Warren Fiskus; Chuandong Geng; Sue Anne Chew; Christopher Foley; Shrijal S Shah; John Shou; Junaith S Mohamed; Cristian Coarfa; Bert W O'Malley; Nicholas Mitsiades Journal: Mol Endocrinol Date: 2015-06-12
Authors: G Brunner; M Reitz; A Heinecke; A Lippold; C Berking; L Suter; J Atzpodien Journal: J Cancer Res Clin Oncol Date: 2012-10-09 Impact factor: 4.553
Authors: Emanuelle M Rizk; Angelina M Seffens; Megan H Trager; Michael R Moore; Larisa J Geskin; Robyn D Gartrell-Corrado; Winston Wong; Yvonne M Saenger Journal: Am J Clin Dermatol Date: 2020-02 Impact factor: 7.403
Authors: Stanley P L Leong; Martin C Mihm; George F Murphy; Dave S B Hoon; Mohammed Kashani-Sabet; Sanjiv S Agarwala; Jonathan S Zager; Axel Hauschild; Vernon K Sondak; Valerie Guild; John M Kirkwood Journal: Clin Exp Metastasis Date: 2012-08-15 Impact factor: 5.150
Authors: Jacob S Ankeny; Brian Labadie; Jason Luke; Eddy Hsueh; Jane Messina; Jonathan S Zager Journal: Clin Exp Metastasis Date: 2018-05-02 Impact factor: 5.150
Authors: A Mitra; C Conway; C Walker; M Cook; B Powell; S Lobo; M Chan; M Kissin; G Layer; J Smallwood; C Ottensmeier; P Stanley; H Peach; H Chong; F Elliott; M M Iles; J Nsengimana; J H Barrett; D T Bishop; J A Newton-Bishop Journal: Br J Cancer Date: 2010-09-21 Impact factor: 7.640